{
    "clinical_study": {
        "@rank": "99037", 
        "acronym": "SHIVA", 
        "arm_group": [
            {
                "arm_group_label": "Standard chemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Treatment choice is based on Investigator decision."
            }, 
            {
                "arm_group_label": "Personalized treatment", 
                "arm_group_type": "Experimental", 
                "description": "Targeted therapy based on the patient molecular profil (if there is at least one abnormality that could be targeted)\nElligible therapies in this trial are :\nImatinib Everolimus Vemurafenib Sorafenib Erlotinib Lapatinib Trastuzumab Dasatinib Tamoxifen (or letrozole if contra-indication) Abiraterone"
            }
        ], 
        "brief_summary": {
            "textblock": "SHIVA is a proof of concept randomized phase II trial which compares two treatment\n      strategies for patients with refractory cancer.\n\n      From a tumor biopsy, a molecular profile of the disease is established (mutations,\n      amplifications, hormone receptor status). If a molecular abnormality is identified for which\n      an approved targeted agent is available, patients are randomized randomized between two\n      arms:\n\n        -  Targeted therapy based on the molecular profile\n\n        -  Conventional therapy based on investigator's choice.\n\n      A cross-over is proposed at disease progression."
        }, 
        "brief_title": "A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer", 
        "condition": "Reccurent/Metastatic Solid Tumor Disease", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patient with recurrent/metastatic solid tumor who failed or are not candidate for\n             treatments usually proposed in first intentions and for whom a prospective clinical\n             trial has been indicated in a tumor board\n\n          2. ECOG performance status of 0 or 1\n\n          3. Biopsiable disease (tumor biopsy mandatory for tumor profiling). The biopsy can be\n             performed when patients are being treated with standard therapy for their\n             recurrent/metastatic cancer if it is not planned to treat them with molecularly\n             targeted agents in the future.\n\n          4. Measurable disease\n\n          5. Adequate renal function defined by a serum creatinine <1.5xUNL (upper normal limit)\n\n          6. Adequate liver function test defined by SGOT & SGPT <3xUNL (5xUNL in case of liver\n             metastases), and bilirubin level <1.5xUNL\n\n          7. Adequate bone marrow function defined by platelets >100,000/mm3, hemoglobin >10 g/dL,\n             and neutrophils >1,000/mm3\n\n          8. Patients must be affiliated to the French Social Security System\n\n          9. Signed informed consent\n\n         10. For female of child-bearing potential: a negative pregnancy test <72 hours before\n             starting study treatment is required. If sexually active, female of childbearing\n             potential must use \"highly effective\" methods of contraception for the study duration\n             and for 3 months following the last treatment\n\n         11. For male of reproductive potential: any sexually active male patient must use a\n             condom while on study treatment and for 3 months following the last treatment\n\n         12. Agreement to send the CD-ROMs of imaging for central review\n\n        Exclusion Criteria:\n\n          1. Patients who have only bone and/or brain metastases\n\n          2. Patients whose brain metastases have not been controlled for >3 months\n\n          3. Patient participating in another clinical trial with an experimental drug\n\n          4. Patients who are candidate to receive a molecularly targeted agent that is approved\n             for their disease\n\n          5. Anticoagulation with anti-vitamin K (Low Molecular Weight Heparin [LMWH] is allowed)\n\n          6. Patients with other concurrent severe and/or uncontrolled medical disease which could\n             compromise participation in the study, including uncontrolled diabetes, cardiac\n             disease, uncontrolled hypertension, congestive cardiac failure, ventricular\n             arrhythmias, active ischemic heart disease, myocardial infection within one year,\n             chronic liver or renal disease, active gastrointestinal tract ulceration, severely\n             impaired lung function\n\n          7. Pregnant and/or breastfeeding women\n\n          8. Individually deprived of liberty or placed under the authority of a tutor\n\n          9. Patients with any psychological, familial, sociological or geographical condition\n             potentially hampering compliance with the study protocol and follow-up schedule\n\n         10. Known HIV, HBV, or HCV infection\n\n        Eligibility criteria for the randomized part :\n\n          1. Identification of tumor molecular abnormalities for which the Therapeutic Decision\n             Committee (TDC) recommends a molecularly targeted therapy available in the context of\n             the trial (even if the molecular profile is incomplete)\n\n          2. Therapy recommended by the TDC is not approved for the patient's disease\n\n          3. ECOG performance status of 0 or 1\n\n          4. Adequate renal function defined by a serum creatinine <1.5xUNL\n\n          5. Adequate liver function tests defined by SGOT & SGPT <3xUNL (5xUNL in case of liver\n             metastases), and bilirubin level <1.5xUNL\n\n          6. Adequate bone marrow function defined by platelets >100,000/mm3, hemoglobin >8 g/dL,\n             and neutrophils >1,000/mm3\n\n          7. Albumin, LDH and number of metastatic sites have been documented (in order to\n             determine the RMH prognostic score)\n\n          8. LVEF >50%\n\n          9. QTc <480 ms on ECG"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01771458", 
            "org_study_id": "IC 2012-04"
        }, 
        "intervention": [
            {
                "arm_group_label": "Personalized treatment", 
                "intervention_name": "Targeted therapy based on molecular profiling : Imatinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Standard chemotherapy", 
                    "Personalized treatment"
                ], 
                "intervention_name": "Tumor biopsy", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Standard chemotherapy", 
                "intervention_name": "Standard Chemotherapy", 
                "intervention_type": "Drug", 
                "other_name": "Based on each investigator choice"
            }, 
            {
                "arm_group_label": "Personalized treatment", 
                "intervention_name": "Targeted therapy based on molecular profiling : Everolimus", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Personalized treatment", 
                "intervention_name": "Targeted therapy based on molecular profiling : Vemurafenib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Personalized treatment", 
                "intervention_name": "Targeted therapy based on molecular profiling : Sorafenib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Personalized treatment", 
                "intervention_name": "Targeted therapy based on molecular profiling : Erlotinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Personalized treatment", 
                "intervention_name": "Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Personalized treatment", 
                "intervention_name": "Targeted therapy based on molecular profiling : Dasatinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Personalized treatment", 
                "intervention_name": "Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Personalized treatment", 
                "intervention_name": "Targeted therapy based on molecular profiling : Abiraterone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tamoxifen", 
                "Letrozole", 
                "Trastuzumab", 
                "Imatinib", 
                "Sorafenib", 
                "Lapatinib", 
                "Sirolimus", 
                "Everolimus", 
                "Erlotinib", 
                "Dasatinib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metastatic/Reccurent", 
            "Solid Tumor", 
            "Refractory", 
            "Molecular profile", 
            "Targeted treatment"
        ], 
        "lastchanged_date": "March 3, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Nicolas ISAMBERT, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Dijon", 
                        "country": "France", 
                        "zip": "21079"
                    }, 
                    "name": "Centre r\u00e9gional de lutte contre le cancer de Bourgogne Georges Fran\u00e7ois Leclerc"
                }, 
                "investigator": {
                    "last_name": "Nicolas ISAMBERT, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Olivier TREDAN, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69373"
                    }, 
                    "name": "Centre Leon Berard"
                }, 
                "investigator": {
                    "last_name": "Olivier TREDAN, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Anthony GONCALVES, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13009"
                    }, 
                    "name": "Institut Paoli Calmettes"
                }, 
                "investigator": {
                    "last_name": "Anthony GONCALVES, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Christophe Le Tourneau, MD", 
                    "phone": "+33 1 44 32 44 07"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75248"
                    }, 
                    "name": "Insitut Curie"
                }, 
                "investigator": {
                    "last_name": "Christophe Le Tourneau, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Emmanuel MITRY, DOCTOR"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint-cloud", 
                        "country": "France", 
                        "zip": "92210"
                    }, 
                    "name": "Institut Curie Hopital Rene Huguenin"
                }, 
                "investigator": {
                    "last_name": "Emmanuel MITRY, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Mario CAMPONE, DOCTOR"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint-herblain", 
                        "country": "France", 
                        "zip": "44000"
                    }, 
                    "name": "Institut de canc\u00e9rologie de l'Ouest Centre Ren\u00e9 Gauducheau"
                }, 
                "investigator": {
                    "last_name": "Mario CAMPONE, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jean-Pierre DELORD, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31052"
                    }, 
                    "name": "Institut Claudius R\u00e9gaud"
                }, 
                "investigator": {
                    "last_name": "Jean-Pierre DELORD, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "C\u00e9line GAVOILLE, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Vandoeuvre Les Nancy", 
                        "country": "France", 
                        "zip": "54500"
                    }, 
                    "name": "Centre Alexis Vautrin"
                }, 
                "investigator": {
                    "last_name": "C\u00e9line GAVOILLE, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Proof-of-concept Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer.", 
        "overall_contact": {
            "email": "patricia.tresca@curie.net", 
            "last_name": "Patricia TRESCA, MD"
        }, 
        "overall_official": {
            "affiliation": "Institut Curie", 
            "last_name": "Christophe LE TOURNEAU, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Tumor evaluation according to RECIST 1.1 criteria (every 2 months)", 
            "measure": "Patient's progression free survival (according RECIST 1.1) of targeted therapy based on molecular profiling versus conventional chemotherapy."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01771458"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Tumor evaluation according to RECIST 1.1 criteria (every 2 months)", 
                "measure": "Overall response rate (ORR)"
            }, 
            {
                "measure": "Overall Survival (OS)"
            }, 
            {
                "measure": "Treatments side effects assessement according to the NCI CTCAE v4.03 scale."
            }, 
            {
                "description": "Evaluation of tumor growth before and during the study (according to RECIST 1.1)", 
                "measure": "Treatment effect variations as defined by tumor growth according to the altered signaling pathway"
            }, 
            {
                "description": "Tumor evaluation according to RECIST 1.1 criteria (every 2 months)", 
                "measure": "Patient's progression free survival (according RECIST 1.1) of targeted therapy based on molecular profiling versus conventional chemotherapy after cross-over."
            }, 
            {
                "description": "Comparing treatment efficacy to ctDNA level (before and during treatment course)", 
                "measure": "Evaluation of the ability of ctDNA to early predict treament efficacy"
            }, 
            {
                "measure": "Evaluation of the medico-economic impact of the experimental strategy"
            }, 
            {
                "description": "Number of screened patients. Number of patient with a molecular full profil in the timeframe (4 weeks between tumor biopsy and SHIVA's committees decision).\nNumber of randomized patient.", 
                "measure": "Technical feasability of the SHIVA trial: number of screened patient compared to number of patients elligible to randomization."
            }
        ], 
        "source": "Institut Curie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institut Curie", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}